Brief: Cognition Therapeutics Presents Proteomic Biomarker Data Of CT1812
28/03/2023 13:18
March 28 (Reuters) - Cognition Therapeutics Inc
CGTX.O :
* COGNITION THERAPEUTICS PRESENTS PROTEOMIC BIOMARKER DATA
DEMONSTRATING PROMINENT EFFECTS OF CT1812 IN ALTERING UNDERLYING
ALZHEIMER’S DISEASE PROCESSES
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB